title: [Treatment for acute promyelocytic leukemia].
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D060830:Consolidation Chemotherapy; D004211:Disseminated Intravascular Coagulation / Q000209:etiology / Q000517:prevention & control; D050939:Gene Fusion; D006801:Humans; D060828:Induction Chemotherapy; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D060046:Maintenance Chemotherapy; D058990:Molecular Targeted Therapy; D009687:Nuclear Proteins / Q000235:genetics; D010087:Oxides / Q000008:administration & dosage*; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid / Q000235:genetics; D012008:Recurrence; D012074:Remission Induction; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D014157:Transcription Factors / Q000235:genetics; D014212:Tretinoin / Q000008:administration & dosage*; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D001152:Arsenicals; D001565:Benzoates; D009687:Nuclear Proteins; D010087:Oxides; D000071156:Promyelocytic Leukemia Protein; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C061133:tamibarotene; C070576:PML protein, human; D014212:Tretinoin; D000077237:Arsenic Trioxide